This multitargeted regimen addresses the biologic heterogeneity of MCL and permits flexible MRD-guided decisions on consolidation and maintenance. Trial Registration: ClinicalTrials.gov identifier: NCT04626791.

1 day ago

Journal

clonoSEQ®

Rituxan (rituximab) • cytarabine • bortezomib • Calquence (acalabrutinib)

19-C-0116: Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma (clinicaltrials.gov)

P2, N=132, Recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2030 --> Mar 2031 | Trial primary completion date: May 2026 --> May 2027

1 day ago

Trial completion date • Trial primary completion date

ALK (Anaplastic lymphoma kinase) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)

Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • Calquence (acalabrutinib)

The CARDIOPROTECT Trial (clinicaltrials.gov)

P2, N=60, Not yet recruiting, Beth Israel Deaconess Medical Center

1 day ago

New P2 trial

Rituxan (rituximab) • cyclophosphamide • pegylated liposomal doxorubicin • vincristine • prednisone • Truxima (rituximab-abbs) • Myocet (non-pegylated liposomal doxorubicin) • Polivy (polatuzumab vedotin-piiq) • dexrazoxane

Mapping B-cell Biology Across the Cardiovascular Territories of Giant Cell Arteritis: Towards a New Therapeutic Approach (RituxiMAP GCA) (clinicaltrials.gov)

P=N/A, N=30, Not yet recruiting, University of Edinburgh | Initiation date: Apr 2026 --> Oct 2026

2 days ago

Trial initiation date

Rituxan (rituximab)

AMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The "Glofit-RCHOP Study") (clinicaltrials.gov)

P1, N=15, Not yet recruiting, National Cancer Institute (NCI)

2 days ago

New P1 trial

BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • CD4 (CD4 Molecule)

CD20 positive

Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • Truxima (rituximab-abbs) • Columvi (glofitamab-gxbm) • Mabtas (rituximab biosimilar)

Clinically Amyopathic Dermatomyositis: Epidemiology, Clinical Presentation, Pathophysiology, Treatment, and Prognosis: A Systematic Review. (PubMed, Rheumatol Ther)

CADM is a serious, complex disease with a distinct clinical and serological profile, requiring further conceptual refinement and multicenter studies to better characterize this DM phenotype.

2 days ago

Review • Journal

IFIH1 (Interferon Induced With Helicase C Domain 1) • CRP (C-reactive protein)

Rituxan (rituximab) • cyclophosphamide • cyclosporine

Breakfree-SSc: A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis (clinicaltrials.gov)

P3, N=92, Recruiting, Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Initiation date: May 2026 --> Aug 2026

3 days ago

Trial initiation date

Rituxan (rituximab) • cyclophosphamide • nintedanib • fludarabine IV • Actemra IV (tocilizumab) • zolacabtagene autoleucel (BMS-986353)

Diffuse Large B-Cell Lymphoma Presenting With Superior Vena Cava Syndrome and Recurrent Pleural Effusions in a Patient With Angelman Syndrome: A Case Report. (PubMed, Cureus)

The patient was started on rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with a good clinical response. Diagnosis was delayed due to the significant procedural barriers as a result of her small stature and microcephaly associated with her Angelman syndrome. Prompt multidisciplinary evaluation and alternative tissue acquisition were essential for diagnosis and treatment.

3 days ago

Journal • Pleural effusion • IO biomarker

CD20 (Membrane Spanning 4-Domains A1) • CD19 (CD19 Molecule) • CD38 (CD38 Molecule) • CD5 (CD5 Molecule) • CD200 (CD200 Molecule) • MME (Membrane Metalloendopeptidase)

Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone

Clinical and Imaging Cohort of Neuroinflammation Diseases in China (CLUE) (clinicaltrials.gov)

P=N/A, N=1000, Recruiting, Beijing Tiantan Hospital | Trial primary completion date: Dec 2025 --> Dec 2027

3 days ago

Trial primary completion date

Rituxan (rituximab) • cyclophosphamide • Tysabri (natalizumab) • methylprednisolone sodium succinate

Relyage: Assessment of Survival and Autonomy With Rituximab Plus Chemotherapy or Rituximab Plus Lenalidomide for Elderly Patients With Relapsed Diffuse Large B-cell Lymphoma (clinicaltrials.gov)

P2, N=1, Completed, Centre Hospitalier Universitaire, Amiens | Recruiting --> Completed | N=114 --> 1

6 days ago

Trial completion • Enrollment change

CD20 (Membrane Spanning 4-Domains A1)

Rituxan (rituximab) • lenalidomide

Pathogenic Mutations in the Tumor Microenvironment Drive Tumor Progression in Diffuse Large B-Cell Lymphoma Through Tumor-Stroma Cross-Talk. (PubMed, Cancers (Basel))

Despite the incorporation of rituximab into standard chemo-immunotherapy regimen, approximately one-third of patients present with relapsed or refractory disease, implicating the need for improved prognostic markers and therapeutic targets...Functional validation through primary cell culture demonstrated significantly elevated Th2 (IL-4, IL-6, IL-10) and Th17 (IL-17) cytokines in co-cultures containing both neoplastic cells and stromal components, underscoring the role of TME in DLBCL progression. Taken together, this study provides novel insights into stromal mutational signatures and cytokine-mediated tumor-stroma interactions, offering potential prognostic biomarkers and therapeutic targets for the improved management of DLBCL.

6 days ago

Journal • IO biomarker

NOTCH1 (Notch 1) • IL6 (Interleukin 6) • KMT2D (Lysine Methyltransferase 2D) • B2M (Beta-2-microglobulin) • TSC2 (TSC complex subunit 2) • EP300 (E1A binding protein p300) • TNFAIP3 (TNF Alpha Induced Protein 3) • IL10 (Interleukin 10) • TGFB1 (Transforming Growth Factor Beta 1) • IL17A (Interleukin 17A) • NFIB (Nuclear Factor I B) • IL4 (Interleukin 4)

Rituxan (rituximab)